Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
UNIVERSITE EUROMEDITERRANEENNE DE FES holds a patent portfolio in the Biotechnology & Pharmaceuticals technology area. There is 1 pending office action currently active. This action is being reviewed by 1 distinct examiner, SCHMITT, MICHAEL J, in 1 distinct art unit. The 1 pending office action represents the university's current focus in the Biotechnology & Pharmaceuticals sector.
SCHMITT, MICHAEL J is the busiest examiner, responsible for 1 pending office action. Since there is only 1 distinct examiner, the prosecution is centralized under this individual. The presence of 1 distinct art unit indicates a targeted technical review for the university's pending intellectual property.
Practitioners should observe that the 1 distinct examiner handles the entire pending workload, which allows for a consistent prosecution path. The presence of 1 distinct art unit suggests that the university's current filings are targeted toward a specific technical niche. This 1 pending office action is the sole matter currently requiring attention from the patent office for this entity in the Biotechnology & Pharmaceuticals area.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHMITT, MICHAEL J | 1 | 56.8% | +20.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18560280 | ETHACRYNIC ACID DERIVATIVES AS INHIBITORS OF MPRO PROTEASE AND SARS-COV-2 REPLICATION | SCHMITT, MICHAEL J | 5d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18560280 | ETHACRYNIC ACID DERIVATIVES AS INHIBITORS OF MPRO PROTEASE AND SARS-COV-2 REPLICATION | SCHMITT, MICHAEL J | 5d |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18560280 | ETHACRYNIC ACID DERIVATIVES AS INHIBITORS OF MPRO PROTEASE AND SARS-COV-2 REPLICATION | SCHMITT, MICHAEL J | 1629 | §102§112 | Final Rejection | 5d | Pending | Nov 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial